EXAGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.95 USD | +1.56% |
|
+4.84% | -2.01% |
| May. 14 | Cantor Fitzgerald Adjusts Price Target on Exagen to $7 From $5, Maintains Overweight Rating | MT |
| May. 13 | Exagen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Strengths
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -2.01% | 33.88M | C+ | ||
| +25.52% | 88.99B | C+ | ||
| -24.52% | 74.82B | B- | ||
| +1.20% | 26.63B | C+ | ||
| +4.56% | 17.88B | A- | ||
| -14.25% | 16.43B | B | ||
| +2.97% | 15.77B | A- | ||
| +79.20% | 13.21B | C+ | ||
| +70.11% | 13.08B | C- | ||
| +40.44% | 12.9B | B- |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- XGN Stock
- Ratings Exagen Inc.
